Fig. 8: Synergism between disulfiram (DSF) and immune-checkpoint blockade. | Nature Communications

Fig. 8: Synergism between disulfiram (DSF) and immune-checkpoint blockade.

From: Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties

Fig. 8

a–d Effects of combination treatment with DSF and immune-checkpoint inhibitor anti-PD-1 antibody on subcutaneous LLC (b) and B16 (c) tumor growth (n = 9). d The number of Granzyme B+ CD8+ T cells at day 20 post inoculation, detected by flow cytometry (n = 5). e Scheme illustrating the mechanisms by which cytoplasmic protein FROUNT modulates tumor-associated macrophages. The experiment was repeated three times. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with Tukey’s multiple comparison test. Error bars indicate s.e.m.

Back to article page